[
  {
    "ts": "2025-11-28T07:19:40+00:00",
    "headline": "Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]",
    "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-pfizer-inc-071940019.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "1638c2f6-1eae-31b2-920c-6ae29e0ce2fb",
      "content": {
        "id": "1638c2f6-1eae-31b2-920c-6ae29e0ce2fb",
        "contentType": "STORY",
        "title": "Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]",
        "pubDate": "2025-11-28T07:19:40Z",
        "displayTime": "2025-11-28T07:19:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-pfizer-inc-071940019.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-pfizer-inc-071940019.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T07:34:36+00:00",
    "headline": "Is Pfizer Stock Underperforming the Dow?",
    "summary": "While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.",
    "url": "https://www.barchart.com/story/news/36352883/is-pfizer-stock-underperforming-the-dow",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "0a1aab91-9357-3855-ac9d-5d6d0ed8fdd7",
      "content": {
        "id": "0a1aab91-9357-3855-ac9d-5d6d0ed8fdd7",
        "contentType": "STORY",
        "title": "Is Pfizer Stock Underperforming the Dow?",
        "description": "",
        "summary": "While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.",
        "pubDate": "2025-11-28T07:34:36Z",
        "displayTime": "2025-11-28T07:34:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/61a887302d26cd6177d7818a7a970efa",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Pfizer Inc_ logo on iPad-by Koshiro K via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fe3wkcuUuoUxbqrE2923Gg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/61a887302d26cd6177d7818a7a970efa.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qm0032IUrhOXDVM7jj6YOA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/61a887302d26cd6177d7818a7a970efa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/36352883/is-pfizer-stock-underperforming-the-dow",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-stock-underperforming-dow-073436773.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T12:29:00+00:00",
    "headline": "$92.91 Bn Nasal Drug Delivery Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030F",
    "summary": "The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The \"Nasal Drug Delivery Market - Global Industry Size, Share,",
    "url": "https://finance.yahoo.com/news/92-91-bn-nasal-drug-122900022.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "29c560ff-cd51-3db7-b6a1-3aa8bc29d9da",
      "content": {
        "id": "29c560ff-cd51-3db7-b6a1-3aa8bc29d9da",
        "contentType": "STORY",
        "title": "$92.91 Bn Nasal Drug Delivery Market Trends, Opportunities, and Forecasts, 2020-2024 & 2025-2030F",
        "description": "",
        "summary": "The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The \"Nasal Drug Delivery Market - Global Industry Size, Share,",
        "pubDate": "2025-11-28T12:29:00Z",
        "displayTime": "2025-11-28T12:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/833a15cee841b32ee31265c0a5d9ac00",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Nasal Drug Delivery Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v8upBSkrv7gEmhfpCMNILA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/833a15cee841b32ee31265c0a5d9ac00.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/63MMdlhzESN_BA_O.bOB9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/833a15cee841b32ee31265c0a5d9ac00.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/92-91-bn-nasal-drug-122900022.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/92-91-bn-nasal-drug-122900022.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GSK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-28T15:07:21+00:00",
    "headline": "Biotechs Are On A Big Run, And Two Stocks Have Buy Points",
    "summary": "Biotech stocks remain prevalent on the IBD 50 list of winning growth names.  While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases.  Biotech stocks have made tremendous progress off April lows.",
    "url": "https://www.investors.com/stock-lists/ibd-50/biotech-stock-argenx-argx-mirum-pharmaceuticals-mirm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "eafa47c7-5a92-3509-9ea1-fe88400954f9",
      "content": {
        "id": "eafa47c7-5a92-3509-9ea1-fe88400954f9",
        "contentType": "STORY",
        "title": "Biotechs Are On A Big Run, And Two Stocks Have Buy Points",
        "description": "",
        "summary": "Biotech stocks remain prevalent on the IBD 50 list of winning growth names.  While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases.  Biotech stocks have made tremendous progress off April lows.",
        "pubDate": "2025-11-28T15:07:21Z",
        "displayTime": "2025-11-28T15:07:21Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/eafa47c7-5a92-3509-9ea1-fe88400954f9/biotechs-are-on-a-big-run-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/337f1a36ff83b29869e634db0bb39a29",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/97dZJ5VxFNHFMdN4dsVXAA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/337f1a36ff83b29869e634db0bb39a29.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pJ20WvIKy3zHOsswO8kBFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/337f1a36ff83b29869e634db0bb39a29.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/stock-lists/ibd-50/biotech-stock-argenx-argx-mirum-pharmaceuticals-mirm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "ARGNF"
            },
            {
              "symbol": "ARGX"
            },
            {
              "symbol": "STOK"
            },
            {
              "symbol": "MIRM"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]